-+ 0.00%
-+ 0.00%
-+ 0.00%

Journey Medical Q3 2026 net loss narrows 43% to $1.32 million

PUBT·11/12/2026 21:04:28
Listen to the news
Journey Medical Q3 2026 net loss narrows 43% to $1.32 million
  • Journey Medical’s third-quarter 2026 GAAP net loss narrowed 43% year over year to $1.32 million.
  • Total revenues rose 8% to $19 million, driven by continued commercial demand for Emrosi.
  • Emrosi revenues jumped 84% to $9 million, supported by prescription demand growth and an improved mix of prescriptions reimbursed by health plans.
  • Management expects its expanded sales force and increasing formulary additions with national health plans to support further Emrosi adoption.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Journey Medical Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202611121601PRIMZONEFULLFEED9876699) on November 12, 2026, and is solely responsible for the information contained therein.